

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Status: RECRUITING

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

* Adults aged greater than or equal to ($\geq$) 18 years on the day of signing the informed consent form. * Confirmed diagnosis of SCD of any genotype. * Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening. * HU Regimen: * a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening. * or * b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect).

Exclusion Criteria:

* Absolute neutrophil count less than ($<$) 2.5×10^9 cells/Litre at Screening or Baseline (Week 1 Day 1). * If on SCD preventive medication, dose is not stable in the 30 days before Screening.

Conditions & Interventions

Interventions:

BIOLOGICAL: Anumigilimab, DRUG: Placebo

Conditions:

Sickle Cell Disease

Keywords:

Anemia, Genetic Disorder, Vaso-occlusive Crises

More Information

Contact(s): Trial Registration Coordinator - clinicaltrials@cslbehrling.com

Principal Investigator:

IRB

Number:

System ID: NCT07224360

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.